All In Biotech

Drug Trial Radar · NCT07946497

CAPN12 Gene Expression as a Molecular Discriminator

CAPN12 Gene Expression as a Molecular Discriminator Between Methotrexate Treated Chronic Plaque Psoriasis and Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Oct 1, 2027

Study completion Oct 10, 2027

Sponsor

Lead sponsor
South Valley UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early. Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.

Conditions

  • Chronic Plaque Psoriasis
  • Psoriatic Arthritis

Interventions

  • MethotrexateDrug

    to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CAPN12 mRNA expressionTime frame: 3 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • South Valley University Hospital

    Qina, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.